|Bid||0.0000 x 1100|
|Ask||0.0000 x 2200|
|Day's Range||0.5020 - 0.5292|
|52 Week Range||0.4100 - 3.1900|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for NKTR
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript November 7, 2023 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.24 EPS, expectations were $-0.18. Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that today’s conference is […]
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.